Ultragenyx Pharmaceutical
RARE
232 hedge funds and large institutions have $2.81B invested in Ultragenyx Pharmaceutical in 2022 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 94 increasing their positions, 60 reducing their positions, and 37 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 60
27% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 37
20% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $14.4M
4% more funds holding
Funds holding: 223 → 232 (+9)
0.34% more ownership
Funds ownership: 96.58% → 96.91% (+0.34%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less capital invested
Capital invested by funds: $4.03B → $2.81B (-$1.23B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$83.8M |
| 2 |
RI
RTW Investments
New York
|
+$50.7M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$29.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$17.6M |
| 5 |
BlackRock
New York
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$310M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$86.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$42.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$27M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$19.4M |
RARE Hedge Fund Activity: Q3 2022 in Review
232 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2022, worth a combined $2.81B — down 30% from $4.03B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new RARE positions and 37 closed out — a net gain of 10 holders — while 94 added to existing stakes and 60 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $83.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $310M.
- 232 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2022, up from 223 in Q2 2022.
- Funds reported $2.81B of Ultragenyx Pharmaceutical stock for Q3 2022, down 30% quarter-over-quarter.
- 47 funds opened new Ultragenyx Pharmaceutical positions in Q3 2022 and 37 closed out, a net change of +10 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2022 was Wellington Management Group, an estimated $83.8M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2022 was T. Rowe Price Associates, an estimated $310M sold.
Based on aggregated 13F filings for Q3 2022.